Gene-augmented nuclear-targeting SDT significantly induced ICD in colorectal cancer, thus boosting DPPA-1 peptide-based anti-PD-L1 therapy to ablate the primary tumor and suppress metastatic tumors. This evidence concerns the gene CD274 and metastatic neoplasm.